Prevalence of estrogen receptor mutations in patients with metastatic breast cancer

August 11, 2016

A new study published online by JAMA Oncology examines the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.

The activation of the (ER) is a feature of most breast cancers in which ER expression is detected. An aromatase inhibitor (AI) for estrogen deprivation therapy is an effective therapy for those tumors and reduces disease illness and death. Outcomes for patients with ER-positive who are treated with AIs vary considerably, with relapse for some patients within months and after many years for others.

Sarat Chandarlapaty, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center, New York, and coauthors conducted a secondary analysis of cell-free DNA from 541 patients enrolled in a clinical trial to determine the prevalence of mutations and whether they were associated with worse outcomes.

The authors report 29 percent of patients had a mutation in the estrogen receptor and mutation was associated with shorter overall survival, according to the report.

"Mutations in the estrogen receptor are common in patients with metastatic who were previously treated with an and are associated with worse outcomes," the authors conclude.

Explore further: Blood samples analysis finds ESR1 gene mutations prevalent, associated with worse overall survival

More information: JAMA Oncol. Published online August 11, 2016. DOI: 10.1001/jamaoncol.2016.1279

Related Stories

Mutations linked to breast cancer treatment resistance

November 3, 2013

Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients ...

MSK studies highlight potential of liquid biopsy

December 11, 2015

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two ...

Recommended for you

Researchers identify new target for cancer immunotherapy

January 17, 2017

Massachusetts General Hospital investigators have found new evidence that the tumor necrosis factor receptor type II (TNFR2) may be a major target for immuno-oncology treatments, which induce a patient's immune system to ...

Study reveals why cancer cells spread within the body

January 17, 2017

Each day, more than 1,600 people die from cancer in the US, and 450 in the UK, mostly because the disease has spread beyond a stage when surgery is an effective cure and has become resistant to therapy. Despite decades of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.